on EUROFINS SCIENTIFIC SE (isin : FR0014000MR3)
Eurofins Achieves 6.9% Revenue Growth in Q1 2025
Eurofins Scientific SE reported a 6.9% increase in Q1 2025 revenues, reaching €1,767m compared to the previous year. This growth was primarily driven by organic expansion and acquisitions, despite fewer public working days.
In Q1, Eurofins closed 11 acquisitions, including SYNLAB’s clinical diagnostics in Spain, adding over €160m to annual revenues. The company also managed €400m in new hybrid bonds to maintain a strong balance sheet and repurchased 4.78m shares.
The Board proposed a €0.60 per share dividend, subject to upcoming AGM approval. Eurofins aims to maintain a financial leverage range of 1.5-2.5x and lower it towards the range's bottom by 2027, focusing on profitability and disciplined investment management.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EUROFINS SCIENTIFIC SE news